New imaging method could replace risky heart wire test

NCT ID NCT07613996

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a new software-based method called Angio-IMR can diagnose coronary microvascular disease (blockages in tiny heart arteries) as accurately as the current standard test that uses a pressure wire inside the artery. About 192 adults with stable chest pain or suspected heart disease will have their standard angiogram images analyzed by five different software programs under three conditions (rest, mild drug effect, and strong drug effect). The goal is to see which software and condition best matches the wire-based results, potentially offering a safer, wire-free alternative.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Angiography-derived Index of Microcirculatory Resistance (Angio-IMR) — a software-based diagnostic test using standard X-ray images
What this could lead to
If successful, this could provide a safer, simpler way to diagnose coronary microvascular disease without needing a pressure wire inside the heart arteries.
What could go wrong
This is an observational study, not a treatment trial. The new method may not match the accuracy of the wire-based test, and results may vary across different software versions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CORONARY ARTERY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • The First Affiliated Hospital, Sun Yat-sen University

    RECRUITING

    Guangzhou, China

  • Zhongshan Hospital, Fudan University

    RECRUITING

    Shanghai, Please Select, 200000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.